| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FON.13.115 |
| P698 | PubMed publication ID | 24156322 |
| P2093 | author name string | Akiko Kukita | |
| Toshio Kukita | |||
| P2860 | cites work | Emerging Functions of RANKL in Lymphoid Tissues | Q21131222 |
| Expression and function of RANK in human monocyte chemotaxis | Q24299177 | ||
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer | Q24605866 | ||
| Latent bone metastasis in breast cancer tied to Src-dependent survival signals | Q24648828 | ||
| Targeting regulatory T cells in cancer | Q27022348 | ||
| Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice | Q28140546 | ||
| Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases | Q45814967 | ||
| A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 | ||
| Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy | Q46312540 | ||
| Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway | Q47847762 | ||
| Immunolocalization of sclerostin synthesized by osteocytes in relation to bone remodeling in the interradicular septa of ovariectomized rats. | Q50795410 | ||
| Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. | Q51054343 | ||
| CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. | Q51774713 | ||
| The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. | Q51949099 | ||
| A unique domain in RANK is required for Gab2 and PLCgamma2 binding to establish osteoclastogenic signals. | Q53364532 | ||
| The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. | Q53453365 | ||
| Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. | Q54528928 | ||
| Osteoclasts are involved in the maintenance of dormant leukemic cells. | Q54718625 | ||
| Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells | Q57184743 | ||
| RANKL Regulates Fas Expression and Fas-Mediated Apoptosis in Osteoclasts | Q58621561 | ||
| The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development | Q28142247 | ||
| TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src | Q28142620 | ||
| Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival | Q28142897 | ||
| Matrix-embedded cells control osteoclast formation | Q28247746 | ||
| Evidence for osteocyte regulation of bone homeostasis through RANKL expression | Q28247757 | ||
| Denosumab for prevention of fractures in postmenopausal women with osteoporosis | Q28254528 | ||
| Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab | Q28265584 | ||
| Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin | Q28294196 | ||
| Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems | Q28294477 | ||
| RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis | Q28294501 | ||
| Role of the proto-oncogene Pokemon in cellular transformation and ARF repression | Q28303509 | ||
| RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases | Q28303938 | ||
| RANKL-induced DC-STAMP is essential for osteoclastogenesis | Q28504881 | ||
| DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells | Q28506839 | ||
| IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development | Q28508430 | ||
| Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation | Q28575953 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients | Q28740575 | ||
| RANKL Is Necessary and Sufficient to Initiate Development of Antigen-Sampling M Cells in the Intestinal Epithelium | Q29397534 | ||
| Salmonella Transforms Follicle-Associated Epithelial Cells into M Cells to Promote Intestinal Invasion | Q29544752 | ||
| EMT and dissemination precede pancreatic tumor formation | Q29615854 | ||
| c-Src links a RANK/αvβ3 integrin complex to the osteoclast cytoskeleton | Q30010102 | ||
| A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function | Q33542094 | ||
| Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. | Q33958982 | ||
| Mechanisms of bone metastasis | Q33977526 | ||
| Bone metastasis: mechanisms and therapeutic opportunities | Q34025195 | ||
| Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2 | Q34302372 | ||
| Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro | Q34459310 | ||
| Characterization and identification of subpopulations of mononuclear preosteoclasts induced by TNF-α in combination with TGF-β in rats | Q34460755 | ||
| Denosumab in men receiving androgen-deprivation therapy for prostate cancer | Q34570396 | ||
| Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer | Q34629549 | ||
| Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit | Q34750367 | ||
| Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer | Q34813227 | ||
| RANK ligand and osteoprotegerin in myeloma bone disease. | Q34992857 | ||
| Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas | Q39849289 | ||
| Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma | Q39894724 | ||
| Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. | Q39958524 | ||
| RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis | Q39964150 | ||
| Heparin inhibits osteoclastic differentiation and function | Q40019020 | ||
| RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes | Q40050213 | ||
| Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. | Q40166492 | ||
| RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. | Q40258875 | ||
| Regulation of cancer cell migration and bone metastasis by RANKL. | Q40298349 | ||
| Direct stimulation of osteoclastogenesis by MIP-1alpha: evidence obtained from studies using RAW264 cell clone highly responsive to RANKL. | Q40601721 | ||
| Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial | Q41489196 | ||
| Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo | Q41753607 | ||
| Eos, MITF, and PU.1 recruit corepressors to osteoclast-specific genes in committed myeloid progenitors | Q41842422 | ||
| Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. | Q42370034 | ||
| Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study | Q42829926 | ||
| RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells | Q43505096 | ||
| The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells | Q43526008 | ||
| Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis | Q44486779 | ||
| Maspin, the molecular bridge between the plasminogen activator system and beta1 integrin that facilitates cell adhesion | Q35107356 | ||
| Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling | Q35194008 | ||
| The LRF transcription factor regulates mature B cell development and the germinal center response in mice | Q35572435 | ||
| Survival and differentiation of mammary epithelial cells in mammary gland development require nuclear retention of Id2 due to RANK signaling | Q35598825 | ||
| From the ranks of mammary progesterone mediators, RANKL takes the spotlight | Q35659426 | ||
| Stage-specific functions of leukemia/lymphoma-related factor (LRF) in the transcriptional control of osteoclast development | Q35787174 | ||
| Ranking the role of RANK ligand in apoptosis | Q35927923 | ||
| Regulation of apoptosis in osteoclasts and osteoblastic cells | Q36032095 | ||
| Expansion of antigen-specific regulatory T cells with the topical vitamin d analog calcipotriol. | Q36066638 | ||
| CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease | Q36177928 | ||
| Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss | Q36216058 | ||
| Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases | Q36223424 | ||
| Osteocyte RANKL: new insights into the control of bone remodeling | Q36253514 | ||
| Management of bone metastases in refractory prostate cancer--role of denosumab | Q36283689 | ||
| Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors | Q36375584 | ||
| RANKL-RANK interaction in immune regulatory systems | Q36412789 | ||
| Microenvironmental regulation of epithelial-mesenchymal transitions in cancer | Q36831337 | ||
| The Ets transcription factor Spi-B is essential for the differentiation of intestinal microfold cells | Q36991688 | ||
| Osteotropic cancers: from primary tumor to bone | Q37218376 | ||
| NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression | Q37286365 | ||
| Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation | Q37597633 | ||
| Advances in the biology of bone metastasis: how the skeleton affects tumor behavior | Q37774077 | ||
| Synthesis of artificial lymphoid tissue with immunological function | Q37800624 | ||
| The regulation of osteoclast function and bone resorption by small GTPases | Q37903263 | ||
| Denosumab and the current status of bone-modifying drugs in breast cancer | Q37965768 | ||
| The osteoclast and its unique cytoskeleton | Q37968677 | ||
| LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis | Q38349410 | ||
| PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. | Q38744013 | ||
| CXCL10 promotes osteolytic bone metastasis by enhancing cancer outgrowth and osteoclastogenesis. | Q39352921 | ||
| RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis | Q39365550 | ||
| Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells. | Q39379017 | ||
| Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition | Q39405423 | ||
| Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis | Q39441340 | ||
| Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption | Q39640888 | ||
| Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). | Q39750162 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell differentiation | Q210861 |
| P304 | page(s) | 1609-1622 | |
| P577 | publication date | 2013-11-01 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Multifunctional properties of RANKL/RANK in cell differentiation, proliferation and metastasis | |
| P478 | volume | 9 |
| Q98178016 | Can Denosumab be used in combination with Doxorubicin in Osteosarcoma? |
| Q35798899 | Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion |
| Q35894485 | Langerhans cell precursors acquire RANK/CD265 in prenatal human skin |
| Q51349251 | Metastatic process: the seed and the soil from bench to bedside. |
| Q38760500 | MiRNA 34a: a therapeutic target for castration-resistant prostate cancer |
| Q38695062 | Pmepa1 induced by RANKL-p38 MAPK pathway has a novel role in osteoclastogenesis. |
| Q47106594 | RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target? |
| Q52757516 | Receptor Activator of Nuclear Transcription Factor NF-κB (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors. |
Search more.